Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 10, 2022Journal of Crohn s and ColitisOpen Access

What Can IBD Specialists Learn from IL-23 Trials in Dermatology?

View Full Paper
Ask AI
Bookmark
Share

Authors

MVMario ValentiHumanitas UniversityANAlessandra NarcisiHumanitas UniversityGPGiulia PaviaHumanitas University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Valenti et al. (2022) studied this question.

synapsesocial.com/papers/6a819bf40be7de9fdeb95692https://doi.org/10.1093/ecco-jcc/jjac023
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease2010 · 3,143 citations
  2. 2Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis2014 · 320 citations
  3. 3Management of psoriasis as a systemic disease: what is the evidence?2019 · 545 citations
  4. 4Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks2019 · 149 citations